RecruitingNot ApplicableNCT06650813
Adapting the FACETS Program to Sickle Cell Disease
Adapting the FACETS Fatigue Management Program to Sickle Cell Disease
Sponsor
Versailles Hospital
Enrollment
24 participants
Start Date
Jan 10, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
Adaptation of a fatigue management program combining the principles of cognitive-behavioral therapy and energy conservation strategies (FACETS program) for a population of adult patients with sickle cell disease (Drépa-FACETS program).
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Participant having freely given his oral agreement.
- Participant with a major sickle cell syndrome, regardless of genotype (e.g. SS, SC, Sbeta).
- Participant with a sufficient command of spoken and written French to take the assessments, complete the questionnaires, follow the program sessions and carry out the home exercises.
Exclusion Criteria4
- Participant with one or more severe psychiatric pathologies (e.g. severe depression, psychosis) that could interfere with the conduct of the study, in particular the primary and secondary endpoints.
- Participants with another chronic pathology causing fatigue.
- Participants in vaso-occlusive crisis (VOC) or hospitalization.
- Participant under legal protection (guardianship, curatorship, safeguard of justice, deprived of liberty).
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERDrépa-FACETS Program
Drépa-FACETS Program for Sickle Cell Disease
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06650813
Related Trials
The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
NCT0697586554 locations
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
NCT0643908231 locations
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
NCT039378171 location
Sickle Cell Disease and the Genomic and Gene Therapy Needs of Stakeholders
NCT044161781 location
Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor
NCT032143541 location